Personalis, Inc. $PSNL Shares Purchased by Blue Water Life Science Advisors LP

Blue Water Life Science Advisors LP raised its stake in Personalis, Inc. (NASDAQ:PSNL) by 42.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,676,300 shares of the company’s stock after buying an additional 500,900 shares during the period. Personalis makes up approximately 8.7% of Blue Water Life Science Advisors LP’s holdings, making the stock its 6th largest holding. Blue Water Life Science Advisors LP owned about 1.89% of Personalis worth $10,997,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Legal & General Group Plc purchased a new stake in Personalis during the second quarter worth $30,000. Ameritas Investment Partners Inc. acquired a new stake in Personalis in the 2nd quarter valued at about $34,000. Alpha Wealth Funds LLC purchased a new position in Personalis during the 2nd quarter valued at about $66,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Personalis during the 2nd quarter valued at about $75,000. Finally, Focus Partners Wealth acquired a new position in Personalis during the first quarter worth about $47,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Stock Performance

PSNL opened at $9.26 on Wednesday. Personalis, Inc. has a 1 year low of $2.83 and a 1 year high of $11.40. The company’s 50 day simple moving average is $8.90 and its 200 day simple moving average is $6.82. The stock has a market capitalization of $822.29 million, a PE ratio of -10.52 and a beta of 1.99.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The company had revenue of $14.50 million for the quarter, compared to analyst estimates of $13.31 million. As a group, sell-side analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Insider Transactions at Personalis

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the completion of the sale, the chief financial officer directly owned 164,458 shares in the company, valued at $1,772,857.24. This represents a 38.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Christopher M. Hall sold 29,612 shares of Personalis stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total value of $266,211.88. Following the completion of the transaction, the chief executive officer directly owned 148,486 shares in the company, valued at $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PSNL. Needham & Company LLC raised their price objective on shares of Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. BTIG Research boosted their price target on Personalis from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Wednesday, October 8th. Finally, Morgan Stanley raised their price target on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.57.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.